Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02159066
Title LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Binimetinib + Encorafenib + Ribociclib

Binimetinib + Encorafenib

Binimetinib + Capmatinib + Encorafenib

Binimetinib + Buparlisib + Encorafenib

Binimetinib + Encorafenib + Infigratinib

Age Groups: adult
Covered Countries USA | CAN

Additional content available in CKB BOOST